Antiemetic prophylaxis with fosaprepitant and granisetron in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

Karin Melanie Cabanillas Stanchi · Julia Vek · Patrick Schlegel · Joachim Vincent Rupprecht · Tim Flaadt · Simone Weber · Sebastian Michaelis · Peter Lang · Rupert Handgretinger · Michaela Döring

Received: 24 September 2019 / Accepted: 30 January 2020 / Published online: 13 February 2020
© The Author(s) 2020

Abstract

Background Chemotherapy-induced nausea and vomiting (CINV) is a severe and distressing complication during allogeneic hematopoietic stem cell transplantation (alloHSCT). The antiemetic fosaprepitant has shown favorable results in pediatric and adult patients receiving chemotherapy. Data on fosaprepitant in children and adolescents undergoing alloHSCT are missing.

Methods In this non-interventional observation study, 120 children and adolescents with a median age of 11.8 years undergoing alloHSCT after a moderately or highly emetogenic conditioning (MEC or HEC) were analyzed. They received an antiemetic prophylaxis with granisetron (2 × 40 µg/kg d⁻¹) with or without fosaprepitant (4 mg/kg; single dose, max. 1 × 150 mg/kg BW), and were analyzed in the control (CG; n = 60) or fosaprepitant group (FG; n = 60). The efficacy and safety of the two antiemetic prophylaxis regimens were analyzed and compared with respect to the acute (0–24 h) and the delayed (> 24–120 h) CINV phase and > 120–240 h after MEC or HEC administration.

Results During MEC, significantly more patients in the CG experienced vomiting during the first 0–24 h (58.6 vs. 25.0%; p = 0.0156) and during > 24–120 h (93.1% vs. 57.1%; p = 0.0020), compared with the FG. Likewise, significantly more vomiting events (269 vs. 136; p < 0.0001) were registered in the CG. During HEC, significantly more patients in the CG experienced vomiting during the first 0–24 h (32.3 vs. 9.4%; p = 0.0319) compared with the FG. Significantly more vomiting events (241 vs. 99; p < 0.0001) were registered in the CG. Laboratory and clinical adverse events were not significantly different between the two groups (p > 0.05).

Conclusions Antiemetic prophylaxis with fosaprepitant and granisetron was well tolerated, safe, and effective in pediatric patients undergoing alloHSCT. However, larger prospective trials are necessary to evaluate these findings.

Keywords Fosaprepitant · Granisetron · Pediatric · Antiemetic prophylaxis · Chemotherapy-induced nausea and vomiting · Hematopoietic stem cell transplantation

Abbreviations

µg Microgram
5-HT3 5-Hydroxytryptamine 3; serotonin

ALL Acute lymphoblastic leukemia
ALT Alanine aminotransferase
AML Acute myeloid leukemia
AST Aspartate aminotransferase
ATG Anti-thymocyte globulin
BSU Body surface area
BW Bodyweight
CG Control group
CINV Chemotherapy-induced nausea and vomiting
dL Deciliter
FG Fosaprepitant group
Fig. Figure
HEC Highly emetogenic chemotherapy
HSCT Hematopoietic stem cell transplantation

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00432-020-03143-8) contains supplementary material, which is available to authorized users.

Michaela Döring
michaela.doering@med.uni-tuebingen.de

1 Department of General Pediatrics, Hematology/Oncology, University Children’s Hospital Tübingen, Hoppe-Seyler-Str. 1, 72076 Tübingen, Germany
2 Department of Hematology and Oncology, Olghospital Stuttgart, Kriegsbergstrasse 60, 70174 Stuttgart, Germany
**Introduction**

Children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) receive conditioning chemotherapy for several days containing moderately or highly emetogenic agents with or without total body irradiation (TBI). These regimens are usually accompanied by chemotherapy-induced nausea and vomiting (CINV), representing a severe side effect that substantially impairs the patients’ quality of life (Einhorn et al. 2017; Patel et al. 2017b). Despite recent advances in the development of antiemetics and comprehensive prophylaxis regimens including serotonin-, neurokinin- and dopamine-receptor antagonists, the control rates of CINV in children undergoing HSCT remain unsatisfying (Flank et al. 2017; Kusnierczyk et al. 2002).

The updated pediatric guidelines of the Multinational Association of Supportive Care in Cancer (MASCC) recommend an antiemetic prophylaxis with a \(5\)-HT\(_3\) (5-hydroxytryptamine 3; serotonin) receptor antagonist (e.g. granisetron) + dexamethasone (+aprepitant in case of highly emetogenic chemotherapy) for children receiving moderately or highly emetogenic chemotherapy (Dupuis et al. 2017). Based on the favorable experiences, in terms of the safety and efficacy of fosaprepitant, in children undergoing moderately or highly emetogenic chemotherapy, the standard antiemetic prophylaxis regimen at the University Children’s Hospital Tübingen for pediatric patients undergoing allogeneic HSCT was changed from granisetron to a prophylaxis regimen with single-dose intravenous fosaprepitant and granisetron.

In this observational study, the safety and efficacy of single-dose intravenous fosaprepitant in addition to the standard prophylaxis regimen with granisetron in pediatric patients (0.5–17 years of age) undergoing moderately or highly emetogenic conditioning chemotherapy prior to allogeneic HSCT were analyzed and compared to a historical control cohort receiving the standard antiemetic prophylaxis only.

**Patients and methods**

**Study background and design**

In 2017, the institutional standard antiemetic prophylaxis regimen during allogeneic HSCT consisting of granisetron (moderately and highly emetogenic chemotherapy) was complemented by single-dose, intravenous fosaprepitant directly before starting the first application of a highly or moderately emetogenic agent of the conditioning chemotherapy, due to good experiences with fosaprepitant in pediatric patients undergoing chemotherapy for the treatment of hemato-oncological malignancies.

The primary objective of this analysis was to evaluate the safety and efficacy of the standard antiemetic prophylaxis regimen consisting of granisetron during moderately and highly emetogenic conditioning chemotherapy prior to alloHSCT in comparison to the standard prophylaxis regimen with additional single-dose intravenous fosaprepitant prior to the start of the conditioning chemotherapy in pediatric patients.

A total of 60 consecutive patients who underwent alloHSCT between June 2017 and February 2019 and who met the inclusion criteria were analyzed in the fosaprepitant group (FG). As a control group (CG), 60 consecutive pediatric patients who underwent HSCT between November 2015 and May 2017 and who met the inclusion criteria were analyzed.

The inclusion criteria were undergoing allogeneic HSCT, patient age between 0.5 and < 18 years at the time of HSCT, a conditioning chemotherapy regimen containing...
moderately or highly emetogenic agents according to the POGO (Pediatric Oncology Group of Ontario) classifications [minimal, stage 1 (<10% emesis risk); low, stage 2 (10–30%); moderate, stage 3 (30–90%); high, stage 4 (>90%)] (Dupuis et al. 2011), administration of an antiemetic prophylaxis regimen consisting of granisetron only (control group) or granisetron with additional single-dose intravenous fosaprepitant (fosaprepitant group). Antiemetic on-demand medication with dimenhydrinate, metoclopramide or levomepromazine was allowed in both groups.

The exclusion criteria were vomiting or the use of antiemetic drugs or dexamethasone 48 h prior to starting the conditioning chemotherapy, and administration of other NK1- or 5-HT3-receptor antagonists.

The emetogenic potential of the conditioning before HSCT was determined using the POGO classifications (Dupuis et al. 2011). The emetogenic potential of the total body irradiation used was classified according to international guidelines (McKenzie et al. 2019). The administered agent or irradiation with the highest emetogenic potential defined the overall emetogenic potential (classification as moderately or highly emetogenic conditioning).

The observation period was defined as the time between the first administration of a moderately or highly emetogenic agent of the conditioning until 240 h thereafter. The 240 h were divided into three CINV phases: 0–24 h (acute phase), >24–120 h (delayed phase), and >120–240 h. The results of the different analyses were compared to the respective periods.

**Antiemetic prophylaxis**

All antiemetic drugs were administered through a central venous catheter or Hickman catheter.

Patients undergoing a moderately or highly emetogenic conditioning chemotherapy received an antiemetic prophylaxis with granisetron (2×40 µg per kilogram bodyweight (µg per kg BW) and day; max. 2×3 mg per day) during the whole conditioning period; as a slow intravenous (IV) injection within 3 min, starting at least 30 min before starting the conditioning chemotherapy without (control group) or with (fosaprepitant group) fosaprepitant (4.0 mg per kg BW; max. 150 mg; as single-dose IV infusion within 30 min at least 1 h before starting the conditioning chemotherapy).

As on-demand antiemetic medications, dimenhydrinate (3×1.0 mg per kg BW per day; max. 3×62 mg; as a short IV infusion), metoclopramide (2×5–10 mg per day; intravenously), and levomepromazine (0.1 mg per kg BW per day; max. 0.2 mg/kg per day; as 24 h continuous infusion) were allowed.

**Safety and tolerance**

During the observation period, adverse events as defined by the United States National Cancer Institute’s Common Terminology Criteria for Adverse Events were documented and analyzed (U.S. NIH -NCI 2010).

Hepatic and renal laboratory markers as well as electrolytes were monitored daily starting on the day of in-patient admission (Baseline) until in-patient discharge. Baseline values as well as minimum/maximum values (Min/Max) during and values at the end (End) of the observation period were analyzed and compared between the study cohorts. Normal blood concentrations of the parameters were defined as alanine aminotransferase (ALT) ≤ 39 U/L (units per liter), aspartate aminotransferase (AST) ≤ 59 U/L, total bilirubin ≤ 1.1 mg/dL (milligram per deciliter), direct bilirubin ≤ 0.3 mg/dL, creatinine ≤ 0.7 mg/dL, urea ≤ 46 mg/dL, potassium 3.4–4.9 mmol/L (millimol per liter), sodium 134 mmol/L—145 mmol/L, and calcium 2.0–2.6 mmol/L. Increases to >1.5 and >2.5-fold of the normal limits (ALT, AST, indirect bilirubin, direct bilirubin, creatinine and urea) as well as decreases of sodium (<134 mmol/L and <130 mmol/L), potassium (<3.4 mmol/L and <3.0 mmol/L), and calcium (<2.0 mmol/L or and <1.8 mmol/L) were analyzed and compared between the two groups.

**Efficacy**

The efficacy of the antiemetic prophylaxis regimen was determined by the percentage of patients experiencing vomiting, the documented vomiting events, the percentage of patients receiving additional on-demand medication, the number of administered doses of on-demand medication with respect to the administered conditioning regimen (highly or moderately emetogenic conditioning) and the CINV phases (acute 0–24 h, delayed >24–120 h, and >120–240 h after the first administration of a moderately or highly emetogenic chemotherapeutic agent).

As primary endpoints, the percentage of patients who did not experience vomiting during the different phases, as well as the percentage of patients with complete control (complete absence of vomiting without the use of on-demand medication), were analyzed and compared.

**Statistical analysis**

Fisher’s exact test was used for two-sample tests for equality of proportions and applied to the frequencies of clinical parameters in the two treatment groups (FG and CG). The package rateratio.test of R was used to compare the
frequency of the vomiting events and the number of administered doses of on-demand medication between the two study groups.

The Wilcoxon signed-rank test was used to test for differences between the results and the normal range values for the analyzed laboratory parameters.

The Wilcoxon matched-pairs signed-rank test was used for inferential statistical analyses between the baseline values and the maximum/minimum values.

Graphs and statistical tests were created with GraphPad Prism for Windows, version 8 (GraphPad Software Inc., La Jolla, CA, USA), or with R (The R Foundation for Statistical Computing, Institute for Statistics and Mathematics, University of Economics and Business Vienna, Austria). $p$ values of $p < 0.05 (*)$, $p < 0.01 (**)$, $p < 0.001 (***)$, and $p < 0.0001 (****)$ were defined as statistically significant and are illustrated in the bar charts.

Results

Patient characteristics

In this analysis, a total of 120 pediatric and adolescent patients (53 females; 44.2%) with a median age of 11.8 years (range 0.7–17.6 years) at the time of HSCT were analyzed. Of these 120 patients, 60 patients each (50.0%) were analyzed in the fosaprepitant group (FG; median age 11.7 years) or in the control group (CG; median age 11.8 years). The patients underwent allogeneic HSCT for the treatment of acute lymphoblastic leukemia (ALL; $n = 28$; 23.3%), acute myeloid leukemia (AML; $n = 15$; 12.5%), beta thalassemia (n = 17; 14.2%), Blackfan–Diamond anemia (n = 3; 2.5%), myelodysplastic syndromes (MDS; $n = 9$; 7.5%), metachromatic leukodystrophy (n = 11; 9.2%), neuroblastoma (n = 13; 10.8%), rhabdomyosarcoma (n = 3; 2.5%), sickle cell anemia (n = 6; 5.0%), or other hematopoietical malignancies, and non-malignancies (n = 15; 12.5%). The patients received stem cells from a mismatched family donor (MMFD; haploidentical HSCT; $n = 49$; 40.8%), a matched unrelated donor (MUD; $n = 50$; 41.7%), or a matched family donor (MFD; $n = 21$; 17.5%). The patients of the CG and the FG were hospitalized, median 32 days (range 15–91 days) and 35 days (range 20–242), respectively, in the transplantation unit until clinical discharge or transfer to a different unit. All patient characteristics including age and age groups, sex, underlying disease or stem cell donor were not significantly different between both study groups ($p > 0.05$) (Table 1).

Conditioning chemotherapy and irradiation

A brief summary of the administered conditioning chemotherapy and its individual emetogenic potential as defined by the POGO classifications is given in Table 2. Median duration of the conditioning chemotherapy was 8 days (range 7–16 days).

Myeloablative conditioning (MAC) with different combinations of chemotherapy (Treo/Flu/TT, Treo/Flu, Bu/Flu/TT, Bu/Flu/TT/Cyc, Bu/Flu, Bu/Cy/Mel, Bu/Cy, Mel/Flu/TT, Mel/Flu/TT/TBI 7 Gy, Mel/Flu/TT/Cy, TBI/Eto, or TBI/Eto/TT) was administered in 112 out of the 120 (93.3%) pediatric patients from which 58 were analyzed in the fosaprepitant group (96.7%) and 54 were analyzed in the control group (90.0%). Reduced-intensity conditioning (RIC) with Flu/Cy/TT, Flu/Cy/TBI 4 Gy, or Flu/Cy was used in 8 of the 120 patients (6.7%) from which 2 were analyzed in the fosaprepitant group (3.3%) and 6 were analyzed in the control group (10.0%).

In total, moderately emetogenic conditioning was administered in 29 (48.3%) and 28 (46.7%) patients of the control and the fosaprepitant group, respectively; highly emetogenic conditioning was administered in 31 (51.7%) and 32 (53.3%) patients of the control and the fosaprepitant group, respectively ($p > 0.9999$). For GvHD prophylaxis, the patients received cyclosporine A (CSA) ($n = 11$; 9.2%), cyclosporine A + methotrexate ($n = 45$; 37.5%), mycophenolate mofetil ($n = 43$; 35.8%), mycophenolate mofetil + cyclosporine A ($n = 6$; 5.0%), mycophenolate mofetil + cyclosporine A + methotrexate ($n = 9$; 7.5%), or tacrolimus ($n = 9$; 7.5%). Anti-thymocyte globulin (ATG) was administered in 111 patients (92.5%).

Efficacy: moderately and highly emetogenic chemotherapy

Data of all patients were included in the efficacy analysis of the prophylaxis regimen.

In the control group, median 2 (range 1–4) vomiting events per patient occurred within the first 0–24 h, median 2 (range 1–20) during >24–120 h and median 4 (range 1–15) during >120–240 h after administration of the first moderately or highly emetogenic agent in the patients experiencing vomiting. In comparison, patients of the fosaprepitant group experienced median 1 (range 1–4) vomiting event per patient during the first 0–24 h ($p = 0.0005$), median 2 (range 1–7) during >24–120 h ($p = 0.0039$), and median 3 (range 1–14) during >120–240 h ($p < 0.0001$).

In the fosaprepitant group median 5 doses of dimenhydrinate (range 1–10 doses), 3 doses of metoclopramide (range 2–9 doses), and median 5 days with levomepromazine perfusor (range 3–8 days) were administered per patient. In the control group median 4 doses of dimenhydrinate (range 1–11 doses), 7 doses of metoclopramide (range 2–10 doses), and median 4 days with levomepromazine as continuous perfusor (range 3–5 days) were administered per patient.
| Table 1 | Patient characteristics |
|---------|-------------------------|
|         | Control group | Fosaprepitant group | \( p \) value |
|         | \( N = 60 \)  | \( N = 60 \)        |               |
|         | \( n (\%) \)  | \( n (\%) \)        |               |
| Age [years] |                     |                      |               |
| 0.5–<2  | 2 (3.3)         | 2 (3.3)              | > 0.9999     |
| 2–6     | 18 (30.0)       | 16 (26.7)            | 0.8397       |
| 7–12    | 14 (23.3)       | 21 (35.0)            | 0.2280       |
| 13–17   | 26 (43.3)       | 21 (35.0)            | 0.4546       |
| Sex     |                     |                      |               |
| Male    | 35 (58.3)        | 32 (53.3)            | 0.7133       |
| Female  | 25 (41.7)        | 28 (46.7)            | 0.7133       |
| Diagnosis |                 |                      |               |
| Acute lymphoblastic leukemia/relapse | 15 (25.0) | 13 (21.7) | 0.8294 |
| Acute myeloid leukemia/relapse | 5 (8.3) | 10 (16.7) | 0.2693 |
| Beta-thalassemia major | 10 (16.7) | 7 (11.7) | 0.6017 |
| Blackfan–Diamond anemia | 2 (3.3) | 1 (1.7) | > 0.9999 |
| Myelodysplastic syndromes | 2 (3.3) | 7 (11.7) | 0.1629 |
| Metachromatic leukodystrophy | 2 (3.3) | 4 (6.7) | 0.6794 |
| Neuroblastoma | 7 (11.7) | 6 (10.0) | > 0.9999 |
| Rhabdomyosarcoma | 3 (5.0) | 0 (0.0) | 0.2437 |
| Sickle cell anemia | 2 (3.3) | 4 (6.7) | 0.6794 |
| Other | 12 (20.0) | 8 (13.3) | 0.4632 |
| HSCT donor |     |             |               |
| Mismatched family donor (haploidentical) | 25 (41.7) | 24 (40.0) | > 0.9999 |
| Matched unrelated donor | 23 (38.3) | 27 (45.0) | 0.5788 |
| Matched family donor (sibling) | 12 (20.0) | 9 (15.0) | 0.6317 |
| GvHD prophylaxis |             |                      |               |
| Cyclosporine A | 7 (11.7) | 4 (6.7) | 0.5289 |
| Cyclosporine A + MTX | 24 (40.0) | 21 (35.0) | 0.7063 |
| Mycophenolate mofetil | 21 (35.0) | 22 (36.7) | > 0.9999 |
| Mycophenolate mofetil + cyclosporine A | 2 (3.3) | 4 (6.7) | 0.6794 |
| Mycophenolate mofetil + cyclosporine A + MTX | 2 (3.3) | 7 (11.7) | 0.1629 |
| Tacrolimus | 5 (8.3) | 9 (15.0) | 0.3945 |
| Anti-thymocyte globulin | 58 (96.7) | 53 (88.3) | 0.1629 |
During moderately emetogenic chemotherapy, percentages of patients experiencing vomiting were significantly higher in the control group during the first 0–24 h (CG: \(n = 17\); 58.6% vs. FG: \(n = 7\); 25.0%; \(p = 0.0156\)) and >24–120 h (CG: \(n = 27\); 93.1% vs. FG: \(n = 16\); 57.1%; \(p = 0.0020\)) after the administration of the first moderately emetogenic agent. In addition, significantly more patients (\(p = 0.0148\)) in the control group (\(n = 12\); 41.4%) experienced vomiting in all three analyzed time periods compared to the fosaprepitant group (\(n = 3\); 9.4%). Complete absence of vomiting during all three phases occurred in significantly (\(p = 0.0235\)) more patients of the fosaprepitant group (\(n = 5\); 15.6%) compared with the control group (\(n = 0\)) (Fig. 1).

Significantly more vomiting events occurred in the control group during the first 0–24 h (CG: 38 events vs. FG: 12 events; \(p = 0.0005\)), during >24–120 h (CG: 83 events vs. FG: 47 events; \(p = 0.0039\)), and during >120–240 h (CG: 148 events vs. FG: 77 events; \(p < 0.0001\)) (Fig. 1).

The percentage of patients receiving dimenhydrinate (CG: 86.2% vs. FG: 75.0%), metoclopramide (CG: 24.1% vs. FG: 21.4%), or levomepromazine continuous perfusor (CG: 20.7% vs. FG: 14.3%) was not significantly different between both cohorts (\(p > 0.05\)). Administered doses of on-demand medication dimenhydrinate (CG: \(n = 134\) vs. FG: \(n = 100\); \(p = 0.4068\)) and metoclopramide (CG: \(n = 46\) vs. FG: \(n = 24\); \(p = 0.0593\)) were not significantly higher in the control group compared to the fosaprepitant group. The administered days on which levomepromazine perfusor was used were not significantly different between both study groups (CG: \(n = 25\) vs. FG: \(n = 17\); \(p > 0.9999\)) (Fig. 2; Supplementary Table ST1).

During highly emetogenic chemotherapy, percentages of patients experiencing vomiting were as well significantly higher in the control group during the first 0–24 h (CG: \(n = 10\); 32.3% vs. FG: \(n = 3\); 9.4%; \(p = 0.0319\)) but not >24–120 h (CG: \(n = 20\); 64.5% vs. FG: \(n = 13\); 40.6%; \(p = 0.0787\)) after the administration of the first highly emetogenic agent. Significantly more patients (\(p = 0.0127\)) in the control group (\(n = 8\); 25.8%) experienced vomiting in all three analyzed time periods compared to the fosaprepitant group (\(n = 1\); 3.1%). Percentages of complete absence of vomiting (CG: 19.4% vs. FG: 34.4%; \(p = 0.2574\)) and complete control (complete absence of vomiting without the use of on-demand medication; CG: 12.9% vs. FG: 15.6%; \(p = 0.1132\)) during all three phases were not significantly different between the two groups (\(p > 0.05\)) (Fig. 1).

Significantly more vomiting events occurred in the control group during the first 0–24 h (CG: 24 events vs. FG: 5 events; \(p = 0.0004\)), during >24–120 h (CG: 96 events vs. FG: 29 events; \(p < 0.0001\)), and during >120–240 h (CG: 121 events vs. FG: 65 events; \(p < 0.0001\)) (Fig. 1).

The percentage of patients receiving dimenhydrinate (CG: 83.9% vs. FG: 68.8%), metoclopramide (CG: 25.8%
Table 2 Emetogenic potential of the conditioning regimen

| Regimen       | Agent          | Dosage                  | Control group | Fosaprepitant group |
|---------------|----------------|-------------------------|---------------|---------------------|
|               |                |                         | MEC [n]       | HEC [n]             |
|               |                |                         | MEC [n]       | HEC [n]             |
| 1a Treo/Flu/TT| Treosulfan     | 3 × 14 g/m²             | 8             | 4                   | 15 | 5 |
|               | Fludarabine    | 5 × 30 mg/m²            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
| 1b Treo/Flu   | Treosulfan     | 3 × 14 g/m²             |               |                     |
|               | Fludarabine    | 5 × 30 mg/m²            |               |                     |
| 2a Bu/Flu/TT  | Busulfan       | Range 4 × 3.2—4 × 4.0 mg/kg | 6 | 1 | 4 | 2 |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
| 2b Bu/Flu/TT/Cyc | Busulfan     | Range 4 × 3.2—4 × 4.0 mg/kg | 5 | 1 |      |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
|               | Cyclophosphamide | 4 × 40 mg/kg or 2 × 60 mg/kg |      |                 |
| 2c Bu/Flu     | Busulfan       | Range 4 × 3.2—4 × 4.0 mg/kg | 1 |       |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
| 2d Bu/Cy/Mel  | Busulfan       | Range 4 × 3.2—4 × 4.0 mg/kg | 1 | 3 |      |
|               | Fludarabine    | 2 × 60 mg/kg            |               |                     |
|               | Flulphalan     | 2 × 70 mg/m²            |               |                     |
| 2e Bu/Cy      | Busulfan       | Range 4 × 3.2—4 × 4.0 mg/kg | 1 |       |
|               | Fludarabine    | 2 × 60 mg/kg            |               |                     |
| 3a Mel/Flu/TT | Melphalan      | 2 × 70 mg/m²            | 14 | 6 | 6 | 12 |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
| 3b Mel/Flu/TT/TLI | Melphalan   | 2 × 70 mg/m²            | 2 |       |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
|               | TLI            | 7 Gy                    |               |                     |
| 3c Mel/Flu/TT/Cy | Melphalan    | 2 × 70 mg/m²            | 1 |       |
|               | Fludarabine    | 4 × 40 mg/m²            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
|               | Cyclophosphamide | 1 × 60 mg/kg           |               |                     |
| 3d Bu/Cy/Mel  | Busulfan       | 4 × 4.0 mg/kg           | 1 |       |
|               | Cyclophosphamide | 2 × 60 mg/kg          |               |                     |
|               | Melphalan      | 2 × 70 mg/m²            |               |                     |
| 4a TBI/Eto    | TBI            | 12 Gy                   | 5             | 4                   |
|               | Etoposide      | 1 × 60 mg/kg            |               |                     |
| 4b TBI/Eto/TT | TBI            | 12 Gy                   |               |                     |
|               | Etoposide      | 1 × 60 mg/kg            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
| 5 Flu/TT      | Fludarabine    | 4 × 40 mg/m²            | 2 | 1 |      |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
| 6a Flu/Cy/TT  | Fludarabine    | 4 × 40 mg/m²            | 1 |       |
|               | Cyclophosphamide | 2 × 60 mg/kg          |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
|               | Thiotepa       | 1 × 10 mg/kg            |               |                     |
| 6b Flu/Cy/TBI 4 Gy | Fludarabine     | 4 × 40 mg/m²           | 3 |       |
|               | Cyclophosphamide | 2 × 60 mg/kg          |               |                     |
|               | TBI            | 4 Gy                    |               |                     |
Table 2  (continued)

| Regimen | Agent | Dosage | Control group | Fosaprepitant group |
|---------|-------|--------|---------------|---------------------|
|         |       |        | MEC [n]       | HEC [n]            |
|         |       |        |               | MEC [n]          | HEC [n]          |
| Flu/Cy  | Fludarabine | 4×40 mg/m² | 1             |                     |
|         | Cyclophosphamide | 2×60 mg/kg |               |                     |
| Total   |        |        | 29 (48.3)     | 31 (51.7)          |
| (% of cohort) | | | 28 (46.7) | 32 (53.3) |

The table shows the administered conditioning chemotherapy regimens. The overall emetogenic potential of the conditioning chemotherapy was determined by the administered agent with the highest emetogenic potential as determined by the POGO classifications (stages 1–4) (Dupuis et al. 2011). HEC highly emetogenic chemotherapy, MEC moderately emetogenic chemotherapy, n sample size, P value probability value. No statistically significant difference between the two cohorts (p > 0.05).

Fig. 1 Efficacy of antiemetic prophylaxis. The graph shows the efficacy of the respective anti-emetic prophylaxis regimen during a moderately or highly emetogenic conditioning in patients of the control group (CG) or the fosaprepitant group (FG). In addition to the standard prophylaxis with granisetron, the patients of the FG received single-dose intravenous fosaprepitant before the start of conditioning chemotherapy.

a In the fosaprepitant group, significantly fewer patients experienced vomiting during the first 0–24 h, > 24 h–120 h, and >120–240 h after the first administration moderately and highly emetogenic conditioning chemotherapy.

b The percentage of patients without vomiting during all analyzed time periods was significantly higher in the fosaprepitant group (CG: 0% vs. FG: 15.6%; p = 0.0235) during moderately emetogenic chemotherapy. The number of patients with complete control (complete absence of vomiting without the use of on-demand medication) was not significantly different between both study groups.

c The number of vomiting events was significantly higher in the control group during all analyzed time periods and during both moderately and highly emetogenic conditioning. Symbols indicate n.s.; not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Efficacy: haploidentical HSCT and allogeneic HSCT from a MUD/MFD

Comparing the efficacy parameters with respect to the transplantation type (haploidentical HSCT vs. allogeneic HSCT from a matched unrelated or matched family donor (alloMUD/MFD)), the efficacy of the fosaprepitant prophylaxis regimen was significantly superior to the control group regimen without fosaprepitant.

Although the percentage of patients experiencing vomiting was not significantly different between both haploidentical HSCT subcohorts (p > 0.05), the absolute number of vomiting events was significantly lower in the fosaprepitant group compared with the control group during all three time periods (0–24 h: p = 0.0043; > 24–120 h: p = 0.0015; > 120–240 h: p = 0.0420; 0–240 h: p < 0.0006), and significantly less vomiting events occurred (0–24 h: p < 0.0001; > 24–120 h: p < 0.0001; > 120–240 h: p < 0.0001; 0–240 h: p < 0.0001) under fosaprepitant during all three time periods (Supplementary Fig. SF1).

Safety and tolerance

Discontinuation of the antiemetic prophylaxis was not indicated for any of the patients of the two study groups. None of the patients of the control group died during the hospitalization in the transplant unit. Of the fosaprepitant group, 4 patients (6.7%) died median 105 days (range 48–242 days) after HSCT during the in-patient stay. Reasons for death were severe sepsis (n = 1), multi-organ failure (n = 1) and graft-versus-host disease °IV (n = 2).

Median increases or decreases beyond the normal limits of the analyzed hepatic and renal parameters and electrolytes were detected for ALT (p < 0.0001) and direct bilirubin (p < 0.001) in both the control and the fosaprepitant group. However, differences of the increases of these two parameters were not significantly different between the two groups (ALT: p = 0.4971 | direct bilirubin: p = 0.5586). The
percentages of increases ≥ 1.5-fold or ≥ 2.5-fold of the upper normal limit of the parameters ALT, AST, indirect bilirubin, creatinine and urea were not significantly different between both cohorts (p > 0.05). The increase of transaminases and bilirubin can be most likely ascribed to the administered chemotherapy, especially melphalan and busulfan. No significant difference between both cohorts of clinically relevant decreases of the parameters potassium, calcium, and sodium was detected (p > 0.05). Significantly more patients comprised increases of direct bilirubin ≥ 0.45 mg/dL (33.3% vs. 15.0%; p = 0.0319) in the control group (p = 0.0319) (Supplementary Table ST2).

Clinical adverse events were low in both study groups and included erythema (FG: n = 2 vs. CG: n = 0), headache (FG: n = 1 vs. CG: n = 1), sweating (FG: n = 2 vs. CG: n = 1), itching (FG: n = 1 vs. CG: n = 0), and constipation (FG: n = 2 vs. CG: n = 3). No neuropathy symptoms were observed in either group. The occurrence of adverse clinical events was not significantly different in the two study groups (p > 0.05).

Fosaprepitant and aprepitant are moderate to weak inhibitors of the CYP3A4, potentially increasing the area under the curve (AUC) of victim drugs such as cyclophosphamide by 1.25-fold up to 5-fold. Concomitant administration of fosaprepitant and other CYP3A4 substrates (e.g. cyclophosphamide) may influence the toxicity and the efficacy of the chemotherapy regimen (Patel et al. 2017a). Blood levels of the relevant concomitantly administered drugs in this analysis (cyclophosphamide, methylprednisolone) were not assessed.

**Discussion**

Nausea and vomiting are highly distressing complications in pediatric patients undergoing chemotherapy, increasing the risk for malnutrition, severity of mucositis or graft-versus-host disease and other secondary adverse effects (Flank et al. 2017). Up to 80% of the patients undergoing HSCT experience nausea and vomiting despite the use of a comprehensive prophylaxis regimen, and complete control of CINV is usually achieved in only few pediatric patients (Ballen et al. 2001; Duquette et al. 2011; Flank et al. 2017; Kusnierczyk et al. 2002). The development of new or optimization of existing antiemetic prophylaxis strategies is therefore urgently needed to improve these patients’ quality of life and their treatment outcome. Although the newly available NK1-receptor antagonist fosaprepitant has shown a favorable antiemetic efficacy in children undergoing moderately or highly emetogenic chemotherapy (Radhakrishnan et al. 2018; Saito et al. 2019; Shillingburg and Biondo 2014; Timaeus et al. 2018), its use for pediatric patients is not yet proposed by international guidelines (Dupuis et al. 2013, 2017). Study data on fosaprepitant in children undergoing HSCT are currently not available. This is the first report to analyze the efficacy and safety of an antiemetic monophylaxis regimen with granisetron only (control group) in comparison to a regimen consisting of granisetron with additional application of intravenous fosaprepitant in pediatric patients undergoing allogeneic HSCT.

In terms of safety and toxicity of the antiemetic regimen used, a significant difference between the two study cohorts was not detected. None of the patients of both groups was withdrawn secondary to adverse events. New or different adverse reactions to fosaprepitant were not registered.

It was demonstrated that fosaprepitant significantly reduced the percentage of patients experiencing vomiting and the number of vomiting events after both moderately and highly emetogenic conditioning. However, a significantly different use of on-demand medication with dimenhydrinate, metoclopramide, or levomepromazine was not observed between the two groups. To reliably evaluate the effect of fosaprepitant on the experienced nausea, further prospective analyses using a suitable nausea assessment tool are necessary.

Patients undergoing a haploidentical HSCT or an allogeneic HSCT from a MUD or MFD receive a distinctly different conditioning chemotherapy. Patients undergoing haploidentical HSCT (T cell depleted graft) receive ATG and methylprednisolone before starting moderately emetogenic chemotherapy with fludarabine.

In contrast, patients with non-malignant or malignant diseases undergoing allogeneic HSCT with graft from a MUD (alloMUD) receive ATG and methylprednisolone during the administration of emetogenic chemotherapy during the conditioning before HSCT.

Comparing the haploidentical subgroup within the control and the fosaprepitant group, a significant difference of the percentage of patients was not detected, while the number of vomiting events was significantly lower under fosaprepitant. In patients undergoing alloMUD/MFD, the percentage of patients experiencing vomiting and the total number of vomiting events were significantly lower in the fosaprepitant group. The prolonged application of methylprednisolone in patients suffering from non-malignant and malignant diseases and receiving HSCT from a MUD did not comprise a specific antiemetic effect during the three analyzed phases, when compared with patients undergoing haploidentical HSCT and receiving methylprednisolone only during ATG administration before starting moderately or highly emetogenic conditioning chemotherapy.

Similarly, the CINV control rates were considerably higher in a prospective randomized trial analyzing a prophylaxis regimen consisting of fosaprepitant (3 mg/kg BW; single dose), ondansetron (0.3–0.9 mg/kg BW per day; max. 16 mg) and dexamethasone (0.45 mg/kg BW per day), in 163 pediatric patients (median 6 years of age, range 1–12 years).
receiving moderately or highly emetogenic chemotherapy only, when compared to the results of this analysis (Radhakrishnan et al. 2018).

In accordance with previously published data on adult patients undergoing HSCT and pediatric patients receiving highly or moderately emetogenic chemotherapy, the results of our analysis demonstrate a clear benefit of the addition of fosaprepitant to the antiemetic prophylaxis regimen during allogeneic HSCT (Grunberg et al. 2011; Radhakrishnan et al. 2018). A comprehensive and effective antiemetic prophylaxis is particularly difficult to accomplish for pediatric patients undergoing allogeneic HSCT. Especially the use of multiple-day chemotherapy regimens with repeated administration of emetogenic agents seems to complicate this task. Larger, prospective trials are urgently needed to significantly improve the antiemetic supportive care in children during HSCT.

Conclusions

Single-dose fosaprepitant in addition to granisetron was safe and effective as an antiemetic prophylaxis in pediatric patients (0.7–17.6 years of age) undergoing moderately or highly emetogenic conditioning prior to allogeneic HSCT. The antiemetic efficacy was superior to the standard regimen with granisetron only during both moderately and highly emetogenic conditioning. Particularly, additional fosaprepitant significantly reduced the number of vomiting events in the first 240 h after the administration of moderately or highly emetogenic agents. Prospective randomized studies are needed to evaluate these findings.

Acknowledgements

Open Access funding provided by Projekt DEAL. This work was supported by the Stefan-Morsch-Stiftung, Birkenfeld, Germany, and the Förderverein für Krebskranke Kinder Tübingen e.V., Tübingen, Germany.

Author contributions

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This analysis was performed in accordance with the Helsinki declaration and with the standards of the institutional ethics committee. An ethics vote was granted by the Ethics Committee of the University of Tübingen (726/2018BO2). Baseline demographics, clinical factors, and survival rates were abstracted from clinical and research records on all patients and maintained on a prospective basis.

Acknowledgements

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20:450–458. https://doi.org/10.1634/theoncologist.2014-0229

Ballen KK, Hesketh AM, Heyes C, Becker PS, Emmons RV, Fogarty K, LaPointe J, Liu Q, Hsieh CC, Hesketh PJ (2001) Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 28:1061–1066. https://doi.org/10.1038/sj.bmt.1703280

Celio L, Ricchini F, De Braud F (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7:391–400. https://doi.org/10.2147/paa.s31288

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005

Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57:191–198. https://doi.org/10.1002/pbc.23114

Dupuis LL, Boodhan S, Holdsworth M, Robison PD, Hain R, Portwine C, O’Shaughnessy E, Sung L (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60:1073–1082. https://doi.org/10.1002/pbc.24508

Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323–331. https://doi.org/10.1007/s00520-016-3384-y

Duquette D, Adam JP, Goulet D, Delage R (2011) Retrospective analysis of the efficacy of antiemetic prophylaxis in different preparative regimens for autologous and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 17:S282. https://doi.org/10.1016/j.bbmt.2018.06.005

Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308. https://doi.org/10.1007/s00520-016-3449-y
European Medicines Agency (EMA)—Committee for Medicinal Products for Human Use (CHMP) (2018) Assessment report Ivemend—Procedure No. EMEA/H/C/000743/II/0037. https://www.ema.europa.eu/documents/variation-report/ivemend-h-c-743-ii-0037-epar-assessment-report-variation_en.pdf. Accessed 12 Dec 2018

Flank J, Sparavalo J, Vol H, Hagen L, Stuhler R, Chong D, Courtney S, Doyle JJ, Gassas A, Schechter T, Dupuis LL (2017) The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study. Bone Marrow Transplant 52:1294–1299. https://doi.org/10.1038/bmt.2017.112

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29:1495–1501. https://doi.org/10.1200/jco.2010.31.7859

Kusnierczyk NM, Saunders EF, Dupuis LL (2002) Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 30:119–124. https://doi.org/10.1038/sj.bmt.1703579

McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C, Chan S, Pidduck W, Razvi Y, Bushehri A, Chow E (2019) Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer 27:783–791. https://doi.org/10.1007/s00520-018-4586-2

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL (2017a) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13322

Patel P, Robinson PD, Thackray J, Flank J, Holdsworth MT, Gibson P, Orsey A, Portwine C, Freedman J, Madden JR, Phillips R, Sung L, Dupuis LL (2017b) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediatr Blood Cancer. https://doi.org/10.1002/hb2.26542

Radhakrishnan V, Joshi A, Ramamoorthy J, Rajaraman S, Ganesan P, Ganesan TS, Dhanushkodi M, Sagar TG (2018) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer. https://doi.org/10.1002/hb2.27551

Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067–1073. https://doi.org/10.1093/annonc/mds541

Saito Y, Kumamoto T, Arima T, Shiraoka N, Ishimaru S, Sonoda T, Nakajima M, Sugiyama M, Arakawa A, Hashimoto H, Makino Y, Ogawa C, Yamaguchi M (2019) Evaluation of aprepitant and fosaprepitant in pediatric patients. Pediatr int. https://doi.org/10.1111/ped.13780

Shillingburg A, Biondo L (2014) Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther 19:127–131. https://doi.org/10.1586/1551-6776-19.2.127

Timaes S, Elder J, Franco K (2018) Evaluation of the use of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. J Pediatr Hematol Oncol 40:527–531. https://doi.org/10.1097/mph.0000000000001213

U.S. NIH-NCI (2010) Common Terminology Criteria for Adverse Events v4.03 (CTCAE) 2010. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute

US Food and Drug Administration (2018) EMEND—Fosaprepitant Dimeglumine. NDA 022023—SUPPL-17. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM605696.pdf. Accessed 12 Dec 2018

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.